Zydus Lifesci.

Market Cap: Mid Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE010B01027
NSEID: ZYDUSLIFE
BSEID: 532321
View on NSE | View on BSE

INR

904.50

18 (2.03%)

BSENSE

Mar 25

BSE+NSE Vol: 1.4 lacs

{
  "main_header": {
    "sid": 290229,
    "name": "Zydus Lifesci.",
    "stock_name": "Zydus Lifesci.",
    "full_name": "Zydus Lifesciences Ltd",
    "name_url": "stocks-analysis/zydus-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "904.50",
    "chg": 18,
    "chgp": "2.03%",
    "dir": 1,
    "prev_price": "886.50",
    "mcapval": "91,013.86 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532321,
    "symbol": "ZYDUSLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE010B01027",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "1.4 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zydus-lifesci-290229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-ltd-is-rated-sell-by-marketsmojo-3905043",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ZydusLifescienc_mojoScore_3905043.png",
        "date": "2026-03-21 10:10:03",
        "description": "Zydus Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Zydus Lifesciences Ltd Opens with Sharp Gap Down Amid Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-ltd-opens-with-sharp-gap-down-amid-market-concerns-3893904",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ZydusLifescienc_gapdown_3893904.png",
        "date": "2026-03-16 12:10:11",
        "description": "Zydus Lifesciences Ltd commenced trading today with a pronounced gap down, opening 5.84% lower than its previous close, reflecting heightened market apprehension following recent developments. The stock’s weak start adds to a sequence of declines amid broader sector pressures."
      },
      {
        "title": "Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-ltd-is-rated-sell-by-marketsmojo-3882705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ZydusLifescienc_mojoScore_3882705.png",
        "date": "2026-03-10 10:10:02",
        "description": "Zydus Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Zydus Lifesciences Ltd Opens with Significant Gap Down Amid Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-ltd-opens-with-significant-gap-down-amid-market-concerns-3864235",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ZydusLifescienc_gapdown_3864235.png",
        "date": "2026-03-02 10:15:18",
        "description": "Zydus Lifesciences Ltd commenced trading on 2 Mar 2026 with a pronounced gap down, opening at an intraday low of Rs 835.85, reflecting a 9.39% decline from its previous close. This weak start underscores prevailing market apprehensions surrounding the stock, which has now recorded losses for two consecutive sessions."
      },
      {
        "title": "Zydus Lifesciences Gains 2.39%: 3 Key Factors Driving the Weekly Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-gains-239-3-key-factors-driving-the-weekly-momentum-3862707",
        "imagepath": "",
        "date": "2026-02-28 17:05:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>23 Feb:</strong> Stock opens at Rs.907.90 with a 0.77% gain</p>\n                    <p><strong>24 Feb:</strong> Technical momentum shifts amid mixed indicator signals</p>\n                    <p><strong>26 Feb:</strong> Surge in call option activity and open interest amid bullish momentum</p>\n                    <p><strong>27 Feb:</strong> Stock closes at Rs.922.50, down 1.67% on the day but up for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.901.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div>..."
      },
      {
        "title": "Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-ltd-is-rated-sell-by-marketsmojo-3860157",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_mojoScore_3860157.png",
        "date": "2026-02-27 10:10:02",
        "description": "Zydus Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Rising Market Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-rising-market-momentum-3858307",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3858307.png",
        "date": "2026-02-26 15:00:06",
        "description": "Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical major’s stock has outperformed its sector peers, supported by robust volume and rising investor participation, as traders recalibrate their directional bets amid evolving market dynamics."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bullish-market-positioning-3858260",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3858260.png",
        "date": "2026-02-26 14:00:05",
        "description": "Zydus Lifesciences Ltd has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor sentiment. The pharmaceutical mid-cap stock’s open interest jumped by 17.76% to 17,815 contracts, accompanied by robust volume and rising prices, suggesting a potential directional bet by traders amid a backdrop of improving fundamentals and sector outperformance."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bullish-derivatives-activity-3858203",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3858203.png",
        "date": "2026-02-26 13:00:05",
        "description": "Zydus Lifesciences Ltd has witnessed a significant 17.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.85% gain in the stock price, the underlying data reveals a complex interplay of bullish and cautious bets as the pharmaceutical mid-cap navigates sectoral and broader market dynamics."
      }
    ],
    "total": 620,
    "sid": "290229",
    "stock_news_url": "https://www.marketsmojo.com/news/zydus-lifesciences-290229"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Zydus launches Semaglutide Injection in an innovative reusable multi-dose pen device in India",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "19-Mar-2026",
      "details": "Zydus launches Aerolife MiniTM to simplify inhaler use for asthma and COPD patients.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "18-Mar-2026",
      "details": "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has declared <strong>1100%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:5</strong> stock split, ex-date: 06 Oct 15",
          "dt": "2015-10-06",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 05 Apr 10",
          "dt": "2010-04-05",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO

2026-03-21 10:10:03

Zydus Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Zydus Lifesciences Ltd Opens with Sharp Gap Down Amid Market Concerns

2026-03-16 12:10:11

Zydus Lifesciences Ltd commenced trading today with a pronounced gap down, opening 5.84% lower than its previous close, reflecting heightened market apprehension following recent developments. The stock’s weak start adds to a sequence of declines amid broader sector pressures.

Read full news article

Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO

2026-03-10 10:10:02

Zydus Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Zydus Lifesciences Ltd Opens with Significant Gap Down Amid Market Concerns

2026-03-02 10:15:18

Zydus Lifesciences Ltd commenced trading on 2 Mar 2026 with a pronounced gap down, opening at an intraday low of Rs 835.85, reflecting a 9.39% decline from its previous close. This weak start underscores prevailing market apprehensions surrounding the stock, which has now recorded losses for two consecutive sessions.

Read full news article

Zydus Lifesciences Gains 2.39%: 3 Key Factors Driving the Weekly Momentum

2026-02-28 17:05:48

Key Events This Week

23 Feb: Stock opens at Rs.907.90 with a 0.77% gain

24 Feb: Technical momentum shifts amid mixed indicator signals

26 Feb: Surge in call option activity and open interest amid bullish momentum

27 Feb: Stock closes at Rs.922.50, down 1.67% on the day but up for the week

Read full news article

Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO

2026-02-27 10:10:02

Zydus Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Rising Market Momentum

2026-02-26 15:00:06

Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical major’s stock has outperformed its sector peers, supported by robust volume and rising investor participation, as traders recalibrate their directional bets amid evolving market dynamics.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Market Positioning

2026-02-26 14:00:05

Zydus Lifesciences Ltd has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor sentiment. The pharmaceutical mid-cap stock’s open interest jumped by 17.76% to 17,815 contracts, accompanied by robust volume and rising prices, suggesting a potential directional bet by traders amid a backdrop of improving fundamentals and sector outperformance.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

2026-02-26 13:00:05

Zydus Lifesciences Ltd has witnessed a significant 17.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 0.85% gain in the stock price, the underlying data reveals a complex interplay of bullish and cautious bets as the pharmaceutical mid-cap navigates sectoral and broader market dynamics.